Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.50 |
| ▸ | MMP12 | P39900 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.49 |
| ▸ | RELA | Q04206 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | CES1 | P23141 | 2/20 | 0.47 |
| ▸ | WNT3A | P56704 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.46 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.46 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.45 |
| ▸ | HPGDS | O60760 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19544342 | 0.82 | FFAR1 (0.54) | FFAR1MMP12NPC1NFKB1RAB9A | |
| SCHEMBL19544320 | 0.80 | MMP12 (0.47) | FFAR1MMP12NPC1NFKB1RAB9A | |
| SCHEMBL11695487 | 0.78 | HDAC2 (0.67) | FFAR1MMP12SMN1; SMN2HDAC2HDAC1 | |
| SCHEMBL12251221 | 0.78 | MKNK1 (0.58) | MMP12WNT3A | |
| SCHEMBL10094799 | 0.77 | HDAC1 (0.70) | FFAR1HDAC2HDAC1 | |
| SCHEMBL353132 | 0.77 | HDAC2 (0.68) | FFAR1NPC1RAB9ASMN1; SMN2HDAC2 | |
| SCHEMBL14643880 | 0.77 | HDAC2 (0.74) | FFAR1MMP12HDAC2HDAC1 | |
| SCHEMBL7796725 | 0.76 | FFAR1 (0.54) | FFAR1NPC1RAB9ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL30916851 | 0.76 | HDAC2 (0.66) | FFAR1NPC1RAB9ASMN1; SMN2HDAC2 | |
| SCHEMBL14387746 | 0.75 | HDAC1 (0.53) | FFAR1HDAC2HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10259823-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SÀRL (CH) | 2019-04-16 | — | — | US | disclosed |
| US-20170313717-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2017-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170313717-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | GLP1R, GIPR, NPY1R | FFAR1 104/4885MMP12 4516/4885NPC1 2943/4885 |
| US-10259823-B2 | GLP-1 receptor modulators | GLP1R, GIPR, GCGR | FFAR1 105/4885MMP12 4447/4885NPC1 3058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.